Deutsche Bank raised the firm’s price target on Neurocrine to $161 from $160 and keeps a Buy rating on the shares post the Q4 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
- Neurocrine sees FY24 INGREZZA net product sales $2.1B-$2.2B
- Neurocrine reports Q4 adjusted EPS $1.54, consensus $1.14
- NBIX Earnings this Week: How Will it Perform?
- Neurocrine price target raised to $150 from $145 at Barclays